导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.77% | 423/4773 |
| 近一周 | -2.49% | 2337/5462 |
| 近一月 | -9.64% | 4790/5421 |
| 近一季 | -11.18% | 3670/5209 |
| 近半年 | 13.32% | 364/4920 |
| 近一年 | 16.35% | 613/4366 |
| 近两年 | 138.97% | 265/2954 |
| 近三年 | 76.08% | 246/2253 |
| 成立以来 | 0.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.49% 4156/4961 |
75.82% 206/5312 |
- - |
- - |
| 2025 | 35.72% 975/4813 |
2.93% 1234/3635 |
-1.69% 3247/4076 |
48.73% 359/4524 |
-9.83% 4096/4813 |
| 2024 | 16.25% 832/3463 |
-10.83% 2387/2808 |
-6.78% 2012/3014 |
22.65% 457/3129 |
14.03% 129/3463 |
| 2023 | -10.36% 1295/2656 |
12.33% 298/2280 |
-6.54% 1661/2385 |
-11.34% 2055/2515 |
-3.69% 764/2655 |
| 2022 | -31.14% 1649/2207 |
-21.77% 1651/1919 |
1.64% 1443/2016 |
-15.05% 1201/2113 |
1.96% 1078/2208 |
| 2021 | 1.21% 685/1822 |
-10.50% 1115/1255 |
28.09% 53/1330 |
-13.65% 1353/1466 |
2.24% 648/1822 |
| 2020 | - - |
- - |
- - |
- - |
-0.55% 1079/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏上证科创板50成份ETF VS. 长安沪深300非周期A(740101) |